Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Dustin N. Krüger"'
Autor:
Dustin N. Krüger, Matthias Bosman, Emeline M. Van Craenenbroeck, Guido R. Y. De Meyer, Constantijn Franssen, Pieter-Jan Guns
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract Background Doxorubicin (DOX) is used for breast cancer and lymphoma, but can cause cardiotoxicity, arterial stiffness, and endothelial dysfunction. We recently reported SERPINA3N as biomarker of cardiovascular toxicity in patients and mice.
Externí odkaz:
https://doaj.org/article/56a98f05017b45b4b30d87d48e86a2eb
Autor:
Dustin N. Krüger, Matthias Bosman, Charles X.L. Van Assche, Callan D. Wesley, Berta Cillero-Pastor, Leen Delrue, Ward Heggermont, Jozef Bartunek, Guido R. Y. De Meyer, Emeline M. Van Craenenbroeck, Pieter-Jan Guns, Constantijn Franssen
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-17 (2024)
Abstract Background The anthracycline doxorubicin (DOX) is a highly effective anticancer agent, especially in breast cancer and lymphoma. However, DOX can cause cancer therapy-related cardiovascular toxicity (CTR-CVT) in patients during treatment and
Externí odkaz:
https://doaj.org/article/be96370b15b24456a6a68e11cd636233
Autor:
Callan D. Wesley, Annarita Sansonetti, Cedric H. G. Neutel, Dustin N. Krüger, Guido R. Y. De Meyer, Wim Martinet, Pieter-Jan Guns
Publikováno v:
Biology, Vol 13, Iss 10, p 844 (2024)
Proteasome inhibitors such as bortezomib and carfilzomib induce apoptosis and are a cornerstone in the treatment of relapsed or refractory multiple myeloma. However, concerns have emerged concerning their link to cancer therapy-related cardiovascular
Externí odkaz:
https://doaj.org/article/47630c895e1d4d558ebbda20a048bc49
Autor:
Matthias Bosman, Dustin N. Krüger, Kasper Favere, Guido R. Y. De Meyer, Constantijn Franssen, Emeline M. Van Craenenbroeck, Pieter-Jan Guns
Publikováno v:
PLoS ONE, Vol 18, Iss 11 (2023)
Externí odkaz:
https://doaj.org/article/da5c8b0dd0294d69a5b2258ec791f609
Autor:
Matthias Bosman, Dustin N. Krüger, Kasper Favere, Callan D. Wesley, Cédric H. G. Neutel, Birgit Van Asbroeck, Owen R. Diebels, Bart Faes, Timen J. Schenk, Wim Martinet, Guido R. Y. De Meyer, Emeline M. Van Craenenbroeck, Pieter-Jan D. F. Guns
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 23, p 12812 (2021)
Clinical and animal studies have demonstrated that chemotherapeutic doxorubicin (DOX) increases arterial stiffness, a predictor of cardiovascular risk. Despite consensus about DOX-impaired endothelium-dependent vasodilation as a contributing mechanis
Externí odkaz:
https://doaj.org/article/8ef902cdf43d4d1c86a08671e28649fc
Autor:
Timen J. Schenk, Wim Martinet, Kasper Favere, Birgit Van Asbroeck, Dustin N. Krüger, Emeline M. Van Craenenbroeck, Callan D. Wesley, Owen R. Diebels, Guido R.Y. De Meyer, Matthias Bosman, Cédric H. G. Neutel, Pieter-Jan Guns, Bart Faes
Publikováno v:
International Journal of Molecular Sciences; Volume 22; Issue 23; Pages: 12812
International Journal of Molecular Sciences
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
International journal of molecular sciences
International Journal of Molecular Sciences, Vol 22, Iss 12812, p 12812 (2021)
International Journal of Molecular Sciences
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
International journal of molecular sciences
International Journal of Molecular Sciences, Vol 22, Iss 12812, p 12812 (2021)
Clinical and animal studies have demonstrated that chemotherapeutic doxorubicin (DOX) increases arterial stiffness, a predictor of cardiovascular risk. Despite consensus about DOX-impaired endothelium-dependent vasodilation as a contributing mechanis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::886c3ba8b9ce92548218e0d3d99a03fc